Intrexon Corporation (Public - NYSE: XON) forms collaborations to create biologically based products and processes using synthetic biology. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company's synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. Its technologies combine the principles of precision engineering, statistical modeling, automation and production at an industrial scale. The Company's technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing, or LEAP, and ActoBiotics platform.
Russian Fishermen Record a Catch of 4.8 Million Tons in 2024 Russia Fed.
Russian fishermen achieved a total catch of 4.8 million tons of aquatic bioresources, according to the Federal Agency for Fisheries' Industry Monitoring System (ISMS). This milestone highlights si...
FAO Globefish Species Analysis: Tuna Worldwide
Demand from processors remains strong despite higher raw material prices
During the first three-quarters of 2024, overall demand for processed and ready-to-eat tuna remained weak in the Western...
Bribery and High Costs Cloud Argentina’s Hake Quota Allocations Argentina
Almost at the same time that the Federal Fisheries Council unanimously approved the CITC's 15-year allocation of hubbsi hake on December 5, the Federal Prosecutor's Office No. 2 of the Mar del Plata J...
Copyright 1995 - 2024 Seafood Media Group Ltd.| All Rights Reserved. DISCLAIMER
Intrexon Corporation
Shareholder/Associate at:
Print
